Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) (SPARTA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01983241 |
Recruitment Status :
Active, not recruiting
First Posted : November 13, 2013
Last Update Posted : March 7, 2024
|
Sponsor:
Grifols Therapeutics LLC
Information provided by (Responsible Party):
Grifols Therapeutics LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | August 2026 |
Estimated Study Completion Date : | January 2027 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):